chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Immunisation, Interchange of vaccine products, Myalgia, Nasopharyngitis
Clinical narrative: Vomiting for 48 hours starting 24 after vaccination received; Fever; Cold; Muscle aches; Fatigue; Pain continuing; Dose 1 and 2: Moderna; booster dose: Pfizer; Dose number: 3; This is a spontaneous report from 2 contactable reporters, consumer (patient) and consumer (Pfizer employee).  A 46-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in right arm, administration date 16Dec2021 (Lot number: FE3594) at the age of 46 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Penicillin allergy" (unspecified if ongoing), notes: Known allergies: Penicillin. Concomitant medications were not reported. Vaccination history included: Moderna covid-19 vaccine (DOSE 1, SINGLE, Lot number: 006B21A, Anatomical site: Right arm, Route of administration: Intramuscular), administration date: 02Apr2021, when the patient was 45 years old, for COVID-19 immunisation and Moderna covid-19 vaccine (DOSE 2, SINGLE, Lot number: 039B21A, Anatomical site: Right arm, Route of administration: Intramuscular), administration date: 30Apr2021, when the patient was 45 years old, for COVID-19 immunisation. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 16Dec2021, outcome "unknown", described as "Dose 1 and 2: Moderna; booster dose: Pfizer"; IMMUNISATION (non-serious) with onset 16Dec2021, outcome "unknown", described as "Dose number: 3"; VOMITING (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (19Dec2021), described as "Vomiting for 48 hours starting 24 after vaccination received"; PYREXIA (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Fever"; NASOPHARYNGITIS (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Cold"; MYALGIA (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Muscle aches"; FATIGUE (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Fatigue"; PAIN (non-serious) with onset 17Dec2021, outcome "not recovered", described as "Pain continuing". Therapeutic measures were taken as a result of vomiting, pyrexia, nasopharyngitis, myalgia, fatigue and pain.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. It was reported that muscle aches lasted longer. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment for events included Tylenol and Advil.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vomiting
Clinical narrative: Vomiting for 48 hours starting 24 after vaccination received; Fever; Cold; Muscle aches; Fatigue; Pain continuing; Dose 1 and 2: Moderna; booster dose: Pfizer; Dose number: 3; This is a spontaneous report from 2 contactable reporters, consumer (patient) and consumer (Pfizer employee).  A 46-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in right arm, administration date 16Dec2021 (Lot number: FE3594) at the age of 46 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Penicillin allergy" (unspecified if ongoing), notes: Known allergies: Penicillin. Concomitant medications were not reported. Vaccination history included: Moderna covid-19 vaccine (DOSE 1, SINGLE, Lot number: 006B21A, Anatomical site: Right arm, Route of administration: Intramuscular), administration date: 02Apr2021, when the patient was 45 years old, for COVID-19 immunisation and Moderna covid-19 vaccine (DOSE 2, SINGLE, Lot number: 039B21A, Anatomical site: Right arm, Route of administration: Intramuscular), administration date: 30Apr2021, when the patient was 45 years old, for COVID-19 immunisation. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 16Dec2021, outcome "unknown", described as "Dose 1 and 2: Moderna; booster dose: Pfizer"; IMMUNISATION (non-serious) with onset 16Dec2021, outcome "unknown", described as "Dose number: 3"; VOMITING (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (19Dec2021), described as "Vomiting for 48 hours starting 24 after vaccination received"; PYREXIA (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Fever"; NASOPHARYNGITIS (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Cold"; MYALGIA (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Muscle aches"; FATIGUE (non-serious) with onset 17Dec2021, outcome "recovered with sequelae" (an unknown date in Dec2021), described as "Fatigue"; PAIN (non-serious) with onset 17Dec2021, outcome "not recovered", described as "Pain continuing". Therapeutic measures were taken as a result of vomiting, pyrexia, nasopharyngitis, myalgia, fatigue and pain.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. It was reported that muscle aches lasted longer. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Treatment for events included Tylenol and Advil.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: tested positive for Covid; tested positive for Covid; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "tested positive for Covid". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: positive.The reporter learned of an individual who tested positive for Covid approximately three weeks after receiving his booster dose. His first two doses and booster dose were all Pfizer.    No follow-up attempts are possible. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Feeling abnormal, Near death experience
Clinical narrative: I felt like a ''hook'' going to my soul and something is killing me; Something is stealing my soul from me; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NEAR DEATH EXPERIENCE (medically significant), outcome "unknown", described as "I felt like a ''hook'' going to my soul and something is killing me"; FEELING ABNORMAL (non-serious), outcome "unknown", described as "Something is stealing my soul from me"Consumer stated, "Hey, so, I took the vaccine and I have some really bad side effects.Reason for no lot number: of Covid-19 Vaccine was reported as Caller unwilling to complete the report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain, Vaccination site pain
Clinical narrative: pain in the injection area; Five days of headaches; chills; aches; fatigue; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP and Other HCP).  A 33 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 05Sep2021 (Lot number: FF2588) at the age of 33 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LEXIPRO; ZYRTEC [CETIRIZINE HYDROCHLORIDE]; PANTOPRAZOLE; DICYCLOMINE. The following information was reported: VACCINATION SITE PAIN (hospitalization) with onset 05Sep2021, outcome "recovering", described as "pain in the injection area"; HEADACHE (hospitalization) with onset 05Sep2021, outcome "recovering", described as "Five days of headaches"; CHILLS (hospitalization) with onset 05Sep2021, outcome "recovering", described as "chills"; PAIN (hospitalization) with onset 05Sep2021, outcome "recovering", described as "aches"; FATIGUE (hospitalization) with onset 05Sep2021, outcome "recovering", described as "fatigue". The events "pain in the injection area", "five days of headaches", "chills", "aches" and "fatigue" were evaluated at the physician office visit and emergency room visit. It was unknown if therapeutic measures were taken as a result of vaccination site pain, headache, chills, pain, fatigue.  Additional information included: no covid prior vaccination. The patient had no known allergies and had no days hospitalization.  No follow-up attempts are possible. No further information is expected.
Age: 20.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Neoplasm
Clinical narrative: Hard, immovable on back of head behind ear. Changes shape and size approximately every two days. Only on left side.; Dose number: 3; This is a spontaneous report from a contactable reporter (consumer or other non hcp). The reporter is the patient.  A 20-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 03Nov2021 at 12:00 (Lot number: FF8841) at the age of 20 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history was not reported. Concomitant medications included: LEXAPRO; VITAMIN B12; VITAMIN D NOS and LOJAIMIESS. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot Number: ER8737, Anatomical location: Left Arm, Vaccine Administration Time: 14:15), administration date: 02Apr2021, when the patient was 20 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot Number: EW0171, Anatomical location: Left Arm, Vaccine Administration Time: 12:00), administration date: 23Apr2021, when the patient was 20 years old, for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious) with onset 03Nov2021 at 12:00, outcome "unknown", described as "Dose number: 3"; NEOPLASM (non-serious) with onset 18Nov2021 at 10:00, outcome "not recovered", described as "Hard, immovable on back of head behind ear. Changes shape and size approximately every two days. Only on left side". It was unknown whether any therapeutic measures were taken as a result of the NEOPLASM.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19.  No follow-up attempts are possible. No further information is expected.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding, Menstruation irregular
Clinical narrative: Missed period for 2 months; Heavy period and cramps which was not the case before; Heavy period and cramps which was not the case before; This is a spontaneous report from a non-contactable reporter (consumer or other non hcp). The reporter is the patient.  A 49-year-old female patient (not pregnant) received bnt162b2 (COVID-19 VACCINE - MANUFACTURER UNKNOWN), administered in left arm, administration date an unknown date in Nov2021 (Lot number: unknown) at the age of 49 years as dose 2, single for COVID-19 immunisation. Relevant medical history included: "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19?:Yes. Concomitant medications were not reported. Vaccination history included: Covid-19 vaccine manufacture unknown (DOSE 1, SINGLE, Lot number: UNKNOWN), for COVID-19 immunisation.  The following information was reported: MENSTRUATION IRREGULAR (non-serious) with onset an unknown date in Nov2021, outcome "unknown", described as "Missed period for 2 months"; HEAVY MENSTRUAL BLEEDING (non-serious) with onset an unknown date in Nov2021, outcome "unknown", described as "Heavy period and cramps which was not the case before"; DYSMENORRHOEA (non-serious) with onset an unknown date in Nov2021, outcome "unknown", described as "Heavy period and cramps which was not the case before". Therapeutic measures were not taken as a result of menstruation irregular, heavy menstrual bleeding and dysmenorrhoea.  Additional Information: The patient did not receive any other vaccines within four weeks prior to COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Immunisation, Joint range of motion decreased, Product administered at inappropriate site
Clinical narrative: Pt reported terrible shoulder pain 2 days after receiving 3rd dose; Loss of range of motion; Vaccine was administered in the left leg; Dose received: 3; This is a spontaneous report from a contactable reporter (pharmacist).   A 28-year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in left leg, administration date 16Dec2021 at 09:45 (Lot number: FD0809) at the age of 28 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history was reported as unknown. Concomitant medications were not reported. Other vaccinations included: FLUCELVAX taken for Immunisation, start date: 09Dec2021, stop date: 09Dec2021. Vaccination history included: Covid 19 vaccine (DOSE 1, SINGLE, MANUFACTURER UNKNOWN, Lot Number: UNKNOWN), and Covid 19 vaccine (DOSE 2, SINGLE, MANUFACTURER UNKNOWN, Lot Number: UNKNOWN), administration date: 24Apr2021, when the patient was 28 years old, for COVID-19 immunisation.  The following information was reported: PRODUCT ADMINISTERED AT INAPPROPRIATE SITE (non-serious) with onset 16Dec2021 at 09:45, outcome "unknown", described as "Vaccine was administered in the left leg"; IMMUNISATION (non-serious) with onset 16Dec2021 at 09:45, outcome "unknown", described as "Dose received: 3"; ARTHRALGIA (non-serious) with onset 18Dec2021, outcome "unknown", described as "Pt reported terrible shoulder pain 2 days after receiving 3rd dose"; JOINT RANGE OF MOTION DECREASED (non-serious) with onset 18Dec2021, outcome "unknown", described as "Loss of range of motion". It was unknown whether therapeutic measures were taken as a result of the events arthralgia and joint range of motion decreased.  Additional information: The patient had no known allergies. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.   No follow-up attempts are possible. No further information is expected.
Age: 28.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Immunisation, Movement disorder, SARS-CoV-2 test
Clinical narrative: Numbness on left arm; Hard to move around; Dose number: 3; This is a spontaneous report from a non-contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 28 year-old male patient received bnt162b2 (BNT162B2), administered in left arm, administration date 17Dec2021 at 14:30 (Lot number: FH8027) at the age of 28 years as dose 3 (booster), single for COVID-19 immunisation. The patient's relevant medical history was not reported. The patient did not take any concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: ER8729; Route of administration: unspecified), administration date: 09Apr2021, when the patient was 27 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot number: EW0192; Anatomical site: Left arm; Route of administration: unspecified), administration date: 07May2021, when the patient was 27 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 17Dec2021 at 14:30, outcome "unknown", described as "Dose number: 3"; HYPOAESTHESIA (non-serious) with onset 17Dec2021 at 21:00, outcome "not recovered", described as "Numbness on left arm"; MOVEMENT DISORDER (non-serious) with onset 17Dec2021 at 21:00, outcome "not recovered", described as "hard to move around". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of hypoaesthesia and movement disorder.  Additional Information: Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had been tested for COVID-19 and the result was negative. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.  No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chills, Fatigue, Immunisation, Nasal congestion
Clinical narrative: Covid test result: Positive; Covid test result: Positive; Cold symptoms; stuffy nose; sore/scratchy throat; sore/scratchy throat; fatigue; aches; Chills; Dose number: 3; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 52 year-old female patient (not pregnant) received bnt162b2 (COMIRNATY), administered in arm right, administration date 09Nov2021 12:00 (Lot number: EW0196) at the age of 52 years as dose 3 (booster), single, administered in arm right, administration date 29Mar2021 (Lot number: EL3247) as dose 2, single and administered in arm right, administration date 01Mar2021 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: CELECOXIB; ZYRTEC [CETIRIZINE HYDROCHLORIDE]. The patient did not receive any other vaccine in four weeks. The patient did not have covid prior vaccination. Tested for covid post vaccination. The following information was reported: IMMUNISATION (non-serious) with onset 09Nov2021 12:00, outcome "unknown", described as "Dose number: 3"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 20Dec2021, outcome "unknown" and all described as "Covid test result: Positive"; NASOPHARYNGITIS (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "Cold symptoms"; NASAL CONGESTION (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "stuffy nose"; OROPHARYNGEAL PAIN (non-serious), THROAT IRRITATION (non-serious) all with onset 17Dec2021 19:00, outcome "recovering" and all described as "sore/scratchy throat"; FATIGUE (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "fatigue"; PAIN (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "aches"; CHILLS (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "Chills". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (20Dec2021) positive. Therapeutic measures were not taken as a result of nasopharyngitis, nasal congestion, oropharyngeal pain, throat irritation, fatigue, pain, chills.  No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Nasopharyngitis, Oropharyngeal pain, Pain, SARS-CoV-2 test, Throat irritation
Clinical narrative: Covid test result: Positive; Covid test result: Positive; Cold symptoms; stuffy nose; sore/scratchy throat; sore/scratchy throat; fatigue; aches; Chills; Dose number: 3; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 52 year-old female patient (not pregnant) received bnt162b2 (COMIRNATY), administered in arm right, administration date 09Nov2021 12:00 (Lot number: EW0196) at the age of 52 years as dose 3 (booster), single, administered in arm right, administration date 29Mar2021 (Lot number: EL3247) as dose 2, single and administered in arm right, administration date 01Mar2021 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: CELECOXIB; ZYRTEC [CETIRIZINE HYDROCHLORIDE]. The patient did not receive any other vaccine in four weeks. The patient did not have covid prior vaccination. Tested for covid post vaccination. The following information was reported: IMMUNISATION (non-serious) with onset 09Nov2021 12:00, outcome "unknown", described as "Dose number: 3"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 20Dec2021, outcome "unknown" and all described as "Covid test result: Positive"; NASOPHARYNGITIS (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "Cold symptoms"; NASAL CONGESTION (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "stuffy nose"; OROPHARYNGEAL PAIN (non-serious), THROAT IRRITATION (non-serious) all with onset 17Dec2021 19:00, outcome "recovering" and all described as "sore/scratchy throat"; FATIGUE (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "fatigue"; PAIN (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "aches"; CHILLS (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "Chills". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (20Dec2021) positive. Therapeutic measures were not taken as a result of nasopharyngitis, nasal congestion, oropharyngeal pain, throat irritation, fatigue, pain, chills.  No follow-up attempts are possible. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination failure
Clinical narrative: Covid test result: Positive; Covid test result: Positive; Cold symptoms; stuffy nose; sore/scratchy throat; sore/scratchy throat; fatigue; aches; Chills; Dose number: 3; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from product quality group. The reporter is the patient.  A 52 year-old female patient (not pregnant) received bnt162b2 (COMIRNATY), administered in arm right, administration date 09Nov2021 12:00 (Lot number: EW0196) at the age of 52 years as dose 3 (booster), single, administered in arm right, administration date 29Mar2021 (Lot number: EL3247) as dose 2, single and administered in arm right, administration date 01Mar2021 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: CELECOXIB; ZYRTEC [CETIRIZINE HYDROCHLORIDE]. The patient did not receive any other vaccine in four weeks. The patient did not have covid prior vaccination. Tested for covid post vaccination. The following information was reported: IMMUNISATION (non-serious) with onset 09Nov2021 12:00, outcome "unknown", described as "Dose number: 3"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 20Dec2021, outcome "unknown" and all described as "Covid test result: Positive"; NASOPHARYNGITIS (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "Cold symptoms"; NASAL CONGESTION (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "stuffy nose"; OROPHARYNGEAL PAIN (non-serious), THROAT IRRITATION (non-serious) all with onset 17Dec2021 19:00, outcome "recovering" and all described as "sore/scratchy throat"; FATIGUE (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "fatigue"; PAIN (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "aches"; CHILLS (non-serious) with onset 17Dec2021 19:00, outcome "recovering", described as "Chills". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (20Dec2021) positive. Therapeutic measures were not taken as a result of nasopharyngitis, nasal congestion, oropharyngeal pain, throat irritation, fatigue, pain, chills.  No follow-up attempts are possible. No further information is expected.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Axillary pain, Immunisation, Neck pain
Clinical narrative: Sharp pain in the underarm area; Sharp pain in the neck where the trap muscle is; Dose number: 3; This is a spontaneous report from a contactable reporter (consumer or other non HCP). The reporter is the patient.  A 24 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 13Dec2021 at 17:00 (Lot number: FD0809) at the age of 24 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "None" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: ER2613, Anatomical location: Arm Left, Administration Time: 10:00, Route of administration: Unspecified), administration date: 18Mar2021, when the patient was 23 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot Number: EW0151, Anatomical location: Arm Left, Administration Time: 11:45, Route of administration: Unspecified), administration date: 13Apr2021, when the patient was 23 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 13Dec2021 at 17:00, outcome "unknown", described as "Dose number: 3"; AXILLARY PAIN (non-serious) with onset 14Dec2021 at 09:00, outcome "recovering", described as "Sharp pain in the underarm area"; NECK PAIN (non-serious) with onset 14Dec2021 at 09:00, outcome "recovering", described as "Sharp pain in the neck where the trap muscle is". Therapeutic measures were not taken as a result of axillary pain and neck pain. Additional information: It was reported that patient had researched it and it said lymph nodes could be a cause, the supraclavicular and axillary lymph nodes. The patient had no known allergies. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Complex regional pain syndrome, Pain
Clinical narrative: Patient has Chronic Reflex Sympathetic Dystrophy of Right Lower Extremity; had an acute exacerbation of burning pain in the right lower extremity which is the affected limb; This is a spontaneous report from a contactable reporter (physician).   A 56 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 19Nov2021 (Lot number: unknown) at the age of 56 years as dose 2, single for COVID-19 immunisation. Relevant medical history included: "Menopause" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Clindamycin, reaction(s): "Drug allergy", notes: Known allergies: Clindamycin; Bactrim, reaction(s): "Drug allergy", notes: Known allergies: Bactrim and Amoxicillin, reaction(s): "Drug allergy", notes: Known allergies: Amoxicilllin. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE Lot number: UNKNOWN Anatomical location: Arm Right, Route of Administration: Intramuscular), administration date: 15Oct2021, when the patient was 56 years old, for COVID-19 immunisation. The following information was reported: COMPLEX REGIONAL PAIN SYNDROME (non-serious) with onset 19Nov2021, outcome "not recovered", described as "Patient has Chronic Reflex Sympathetic Dystrophy of Right Lower Extremity"; PAIN (non-serious) with onset 19Nov2021, outcome "not recovered", described as "had an acute exacerbation of burning pain in the right lower extremity which is the affected limb". The events "Patient has Chronic Reflex Sympathetic Dystrophy of Right Lower Extremity" and "had an acute exacerbation of burning pain in the right lower extremity which is the affected limb" were evaluated at the physician office visit. Therapeutic measures were taken as a result of complex regional pain syndrome and pain.  Additional information: It has been constant and has not stopped since patient's vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to COVID vaccine. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. Therapeutic measures included gabapentin (MANUFACTURER UNKNOWN) and GRALISE from an unknown date and unknown if ongoing.   The lot number for BNT162b2 was not provided and will be requested during follow up.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Eyelid rash, Immunisation, Lymph node pain, Lymphadenopathy, Rash
Clinical narrative: Lymph node in left arm pit swollen and sore; Lymph node in left arm pit swollen and sore; A quarter size rash on neck started approximately 24 hours post vaccine. Rash spread within 48 hours to cover neck from collar bone up and onto face; Rash on face covers both sides of jaw and part of right eye lid; Rash is red, swollen, tight and feels like sunburn, but does not itch; Dose number 3; This is a spontaneous report received from a contactable reporter (Consumer or other non-HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Dec2021 at 18:00 (Lot number: FJ8757) at the age of 45 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Penicillin allergy" (unspecified if ongoing), notes: Known allergies: Penicillin and "Hay fever" (unspecified if ongoing), notes: Known allergies: seasonal hayfever. There were no concomitant medications. Past drug history included: Aspirin, reaction: "Drug allergy", notes: Known allergies: aspirin. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: EW0150; Administration time: 11:00; Anatomical location: left arm), administration date: 03Apr2021, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot number: EW0161; Administration time: 11:00; Anatomical location: left arm), administration date: 24Apr2021, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 17Dec2021 at 18:00, outcome "unknown", described as "Dose number 3"; LYMPHADENOPATHY (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Lymph node in left arm pit swollen and sore"; LYMPH NODE PAIN (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Lymph node in left arm pit swollen and sore"; RASH (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "A quarter size rash on neck started approximately 24 hours post vaccine. Rash spread within 48 hours to cover neck from collar bone up and onto face"; EYELID RASH (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Rash on face covers both sides of jaw and part of right eye lid"; RASH ERYTHEMATOUS (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Rash is red, swollen, tight and feels like sunburn, but does not itch". It was unknown whether any therapeutic measures were taken as a result of the reported events.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Rash erythematous
Clinical narrative: Lymph node in left arm pit swollen and sore; Lymph node in left arm pit swollen and sore; A quarter size rash on neck started approximately 24 hours post vaccine. Rash spread within 48 hours to cover neck from collar bone up and onto face; Rash on face covers both sides of jaw and part of right eye lid; Rash is red, swollen, tight and feels like sunburn, but does not itch; Dose number 3; This is a spontaneous report received from a contactable reporter (Consumer or other non-HCP). The reporter is the patient.  A 45-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Dec2021 at 18:00 (Lot number: FJ8757) at the age of 45 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Penicillin allergy" (unspecified if ongoing), notes: Known allergies: Penicillin and "Hay fever" (unspecified if ongoing), notes: Known allergies: seasonal hayfever. There were no concomitant medications. Past drug history included: Aspirin, reaction: "Drug allergy", notes: Known allergies: aspirin. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: EW0150; Administration time: 11:00; Anatomical location: left arm), administration date: 03Apr2021, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot number: EW0161; Administration time: 11:00; Anatomical location: left arm), administration date: 24Apr2021, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 17Dec2021 at 18:00, outcome "unknown", described as "Dose number 3"; LYMPHADENOPATHY (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Lymph node in left arm pit swollen and sore"; LYMPH NODE PAIN (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Lymph node in left arm pit swollen and sore"; RASH (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "A quarter size rash on neck started approximately 24 hours post vaccine. Rash spread within 48 hours to cover neck from collar bone up and onto face"; EYELID RASH (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Rash on face covers both sides of jaw and part of right eye lid"; RASH ERYTHEMATOUS (non-serious) with onset 18Dec2021 at 18:00, outcome "not recovered", described as "Rash is red, swollen, tight and feels like sunburn, but does not itch". It was unknown whether any therapeutic measures were taken as a result of the reported events.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Lymphadenopathy
Clinical narrative: Lymphadenopathy around armpit; Dose Number: 3; This is a spontaneous report from a contactable reporter (consumer or other non hcp).   A 25-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in left arm, administration date 16Dec2021 at 14:00 (Lot number: unknown) at the age of 25 years as dose number 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Irritable bowel syndrome" (unspecified if ongoing), notes: IBS and "Clinical depression" (unspecified if ongoing). Concomitant medication included: LEXAPRO. Past drug history included: Lamotrigine, reaction: "Drug allergy". Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot number: Unknown; Route of administration: intramuscular), administration date: an unknown date in Mar2021, when the patient was 25 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot number: unknown, Route of administration: intramuscular), administration date: an unknown date in Apr2021, when the patient was 25 years old, for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious) with onset 16Dec2021 at 14:00, outcome "unknown", described as "Dose Number: 3"; LYMPHADENOPATHY (non-serious) with onset 19Dec2021, outcome "recovering", described as "Lymphadenopathy around armpit". Therapeutic measures were not taken as a result of lymphadenopathy.  Additional information: Prior to vaccination, it was unknown if the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pain, Fatigue, Headache, Immunisation, Lymphadenopathy
Clinical narrative: Fever; Headache; Vomiting; Fatigue; Pain behind eyes; Sore arm; Swollen lymph nodes over 48 hours; dose received :3; This is a spontaneous report from a non-contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 31-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 18Dec2021 at 10:30 (Lot number: FL3197) at the age of 31 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Sulfonamide allergy" (unspecified if ongoing), notes: known allergies: Sulfa drugs. The patient did not receive any concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: ER8735, Anatomical site: Left arm; Administration time: 17:00), administration date: 30Mar2021, when the patient was 31 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot number: ER8731, Anatomical site: Left arm, Administration time: 17:00), administration date: 20Apr2021, when the patient was 31 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 18Dec2021 at 10:30, outcome "unknown", described as "dose received :3"; PYREXIA (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Fever"; HEADACHE (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Headache"; VOMITING (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Vomiting"; FATIGUE (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Fatigue"; EYE PAIN (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Pain behind eyes"; PAIN IN EXTREMITY (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Sore arm"; LYMPHADENOPATHY (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Swollen lymph nodes over 48 hours". Therapeutic measures were not taken as a result of pyrexia, headache, vomiting, fatigue, eye pain, pain in extremity and lymphadenopathy.  Additional Information: Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.   No follow-up attempts are possible. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia, Vomiting
Clinical narrative: Fever; Headache; Vomiting; Fatigue; Pain behind eyes; Sore arm; Swollen lymph nodes over 48 hours; dose received :3; This is a spontaneous report from a non-contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 31-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 18Dec2021 at 10:30 (Lot number: FL3197) at the age of 31 years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Sulfonamide allergy" (unspecified if ongoing), notes: known allergies: Sulfa drugs. The patient did not receive any concomitant medications. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, Lot number: ER8735, Anatomical site: Left arm; Administration time: 17:00), administration date: 30Mar2021, when the patient was 31 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE, Lot number: ER8731, Anatomical site: Left arm, Administration time: 17:00), administration date: 20Apr2021, when the patient was 31 years old, for COVID-19 immunisation.  The following information was reported: IMMUNISATION (non-serious) with onset 18Dec2021 at 10:30, outcome "unknown", described as "dose received :3"; PYREXIA (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Fever"; HEADACHE (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Headache"; VOMITING (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Vomiting"; FATIGUE (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Fatigue"; EYE PAIN (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Pain behind eyes"; PAIN IN EXTREMITY (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Sore arm"; LYMPHADENOPATHY (non-serious) with onset 18Dec2021 at 21:00, outcome "recovering", described as "Swollen lymph nodes over 48 hours". Therapeutic measures were not taken as a result of pyrexia, headache, vomiting, fatigue, eye pain, pain in extremity and lymphadenopathy.  Additional Information: Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.   No follow-up attempts are possible. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Developed a rash to axillary area of R arm where I was injected 12 days after; This is a spontaneous report from a non-contactable reporter (nurse). The reporter is the patient.  A 51-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 01Dec2021 at 10:15 (Lot number: unknown) at the age of 51 years as dose 1, single for COVID-19 immunisation. Relevant medical history included: "Hypertension" (unspecified if ongoing), notes: HTN; "Hair loss" (unspecified if ongoing); "Thalassemia minor" (unspecified if ongoing), notes: Thallasemia minor; "Hyperlipidaemia" (unspecified if ongoing), notes: HLD; "Penicillin allergy" (unspecified if ongoing), notes: Known allergies: PCN and "COVID-19" (unspecified if ongoing), notes: Prior to vaccination, was the patient diagnosed with COVID-19: Yes. Concomitant medication included: BENICAR.  The following information was reported: RASH (non-serious) with onset 12Dec2021, outcome "not recovered", described as "Developed a rash to axillary area of R arm where I was injected 12 days after". Therapeutic measures were not taken as a result of rash.  Additional information: The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Myalgia, Pain in extremity, Pyrexia
Clinical narrative: Fever; Muscle pain; Sore arm; Exhaustion; This is a spontaneous report from a non-contactable reporter (consumer or non-HCP). The reporter is the patient.   A 52-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in left arm, administration date 18Dec2021 at 18:00 (Lot number: unknown) at the age of 52 years as dose 1, single for COVID-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: ALLEGRA and ESTROGEN.  The following information was reported: PYREXIA (non-serious) with onset 19Dec2021 at 08:00, outcome "recovering", described as "Fever"; MYALGIA (non-serious) with onset 19Dec2021 at 08:00, outcome "recovering", described as "Muscle pain"; PAIN IN EXTREMITY (non-serious) with onset 19Dec2021 at 08:00, outcome "recovering", described as "Sore arm"; FATIGUE (non-serious) with onset 19Dec2021 at 08:00, outcome "recovering", described as "Exhaustion". Therapeutic measures were not taken as a result of pyrexia, myalgia, pain in extremity and fatigue.  Additional information: The patient had no known allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit and emergency room/department or urgent care.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.